2024. Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatology Practical & Conceptual. 14, 4 (Oct. 2024), e2024284. DOI:https://doi.org/10.5826/dpc.1404a284.